Target identification, validation and deconvolution

Leveraging advanced functional genomics and comprehensive in vitro/in vivo assay platforms, we collaborate closely with your team to generate proprietary, disease-relevant multi-omics datasets. These datasets are analysed using cutting-edge bioinformatics tools, offering a strong, innovative foundation for discovering and developing your assets, and helping ensure a data-driven and well-supported pathway to progress.

Cell partitioning and barcoding for single-cell sequencing are performed on a chip

Generation of the right model systems

We design and create customised cell models for target identification, validation and mode-of-action studies using CRISPR knock-out and knock-in, RNAi technologies and directed target overexpression. Parental cell lines are chosen to meet your project's specific needs. We work with various cell types, including verified immortalised and cancer cell lines, primary cells, induced pluripotent stem cell (iPSC)-derived cells and purified immune cells from whole blood. Co-culture, 2D culture and 3D culture formats are available.

Target screening

We conduct target screening campaigns using both unbiased and hypothesis-driven methods to better understand genotype-phenotype relationships, build disease-relevant models and elucidate mechanisms of action and biological pathways. We provide phenotypic and genetic screening of your chosen cell model (2D or 3D) in large-scale pooled or arrayed formats using custom or whole-genome targeting libraries (CRISPRn, CRISPRa, CRISPRi, perturb-seq and RNAi). Additionally, we employ advanced bioinformatics tools to support comprehensive data mining and hypothesis generation.

Target deconvolution

Phenotypic small-molecule screens help you discover novel therapeutic candidates. Identifying the direct drug target is crucial for efficient structure–activity relationship studies and rational drug design. Our target deconvolution services, including CRISPR-based screening and proteomics, help ensure precise identification of drug targets. We offer these methods individually or in combination, leveraging our proven expertise to support your drug discovery efforts.

Target Profiling

To assess the role of your targets in the proposed therapeutic context, we conduct a range of analyses, including transcriptomic and proteomic profiling, metabolomics and gene studies (knock-out, knock-down, and over-expression) both in vitro and in vivo. Additionally, we provide extensive bioinformatics support. For broad target profiling, we utilise immunohistochemistry (IHC) on tumor microarrays (TMAs), derived from a comprehensive collection of clinical samples. These arrays represent the most relevant tumor indications and include histopathological assessments.

Assays2Go platform

Discover how our Assays2Go services can enhance your drug discovery process.

Learn more

Illustrative visualization of immune cells, e.g. T cells, launching an attack on a cancer cell

High-throughput screening

With our unique expertise and state-of-the-art HTS equipment, we address a wide range of target classes.

Learn more

Search

Target identification, validation and deconvolution